<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only for interactions with the combinatons daclatasvir/sofosbuvir or ledispavir/sofosbuvir:

Possibly abrupt onset of bradycardia, that can have fatal consequences </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the bitherapy.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the rifampicin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
